{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-266974","form_type":"8-K","ticker":"ADPT","cik":"0001478320","company_name":"Adaptive Biotechnologies Corp","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.492669+00:00","generated_at":"2026-05-17T00:14:58.150642+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Adaptive Biotechnologies Q3 revenue $94M (+102% YoY); MRD profitable, guidance raised","bullets":["Revenue $94.0M (up 102% YoY) includes $33.7M from full amortization of Genentech payment.","MRD revenue $56.8M (+52% YoY); MRD achieved profitability and cash flow positivity with Adj. EBITDA $7.0M.","clonoSEQ test volume 27,111 (+38% YoY); NCCN guidelines updated for CLL MRD-guided treatment duration.","Net income $9.5M vs $32.1M loss in Q3 2024; Adj. EBITDA $28.0M vs $14.3M loss.","FY2025 MRD revenue guidance raised to $202-207M; total operating spend and cash burn guidance reduced."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-266974","json":"https://secwatch.observer/filing/0001193125-25-266974.json","markdown":"https://secwatch.observer/filing/0001193125-25-266974.md","text":"https://secwatch.observer/filing/0001193125-25-266974.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1478320/000119312525266974/0001193125-25-266974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1478320/000119312525266974/adpt-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:14:58.150642+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}